Broussonetine A



Compound IDCDAMM02682
Common nameBroussonetine A
IUPAC name1-hydroxy-13-[4-hydroxy-5-(hydroxymethyl)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypyrrolidin-2-yl]tridecan-4-one
Molecular formulaC24H45NO10

Experimental data

Retention time11.97
Adduct[M+H]+
Actual mz508.309
Theoretical mz508.311
Error3.69
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.0407

Identifiers and class information

Inchi keyLYIJINGICVFWEP-OWXBEFEHNA-N
SmilesO=C(CCCO)CCCCCCCCCC1NC(CO)C(O)C1OC2OC(CO)C(O)C(O)C2O
SuperclassLipids and lipid-like molecules
ClassFatty Acyls

Pharmacokinetic properties

Number of descriptor values(#stars)9
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)24
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)507.62
Computed dipole moment(dipole)2.781
Total solvent accessible surface area (SASA)921.436
Hydrophobic component of SASA (FOSA)603.288
Hydrophilic component of SASA (FISA)318.148
Pie component of the SASA (PISA)0
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1673.09
Number of hydrogen bond donors (donorHB)8
Number of hydrogen bond acceptors (accptHB)18.8
Free energy of solvation of dipole (dip^2/V)0.0046234
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0577082
Globularity descriptor (glob)0.739683
Predicted polarizability in cubic angstroms (QPpolrz)45.393
Predicted hexadecane/gas partition coefficient (QPlogPC16)18.304
Predicted octanol/gas partition coefficient (QPlogPoct)36.536
Predicted water/gas partition coefficient (QPlogPw)29.041
Predicted octanol/water partition coefficient (QPlogPo/w)-1.513
Predicted aqueous solubility (QPlogS)-1.264
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.083
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.47
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.376
Predicted brain/blood partition coefficient (QPlogBB)-4.361
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.798
Predicted skin permeability, log Kp (QPlogKp)-7.141
PM3 calculated ionization potential (IP(ev))9.297
PM3 calculated electron affinity (EA(eV))-0.666
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-1.548
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)207.166
Number of nitrogen and oxygen atoms (#NandO)11
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P06280GLAAlpha-galactosidase AT61339SEA
P06280GLAAlpha-galactosidase AT61339SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
Q9BZP6CHIAAcidic mammalian chitinase (by homology)T51597SEA
P32320CDACytidine deaminase (by homology)T79027SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
O00142TK2Thymidine kinase, mitochondrialT22976SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T22976DI0206Inborn purine/pyrimidine/nucleotide metabolism error[ICD-11: 5C55]O00142TK2

Copyright © 2025